ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1219

Patient Experience of Brain Fog to Inform the Development of a De Novo Patient Reported Outcome (PRO) in Patients with Sjögren’s Disease

Denise Kruzikas1, Ann Eldred2, Shelly Kafka3, Janet Church4, Katherine Hammitt4, Patricia Koochaki5 and Christina O'Donnell6, 1AbbVie, Inc., North Chicago, IL, 2AbbVie, Inc., Lake Bluff, IL, 3AbbVie, Inc., Norristown, PA, 4Sjögren’s Foundation, Reston, VA, 5ICON Clinical Research LLC, Raleigh, NC, 6ICON plc, Raleigh, NC

Meeting: ACR Convergence 2023

Keywords: Cognitive dysfunction, Patient reported outcomes, quality of life, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1200–1220) Patient Outcomes, Preferences, & Attitudes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Brain fog is commonly reported by SJD patients, though limited evidence exists to understand patient experiences. Various terms may be used to describe brain fog, including mental or cognitive fatigue and cognitive dysfunction. While cognitive difficulties are typically assessed via battery testing, there is no brain fog PRO to assess related patient symptoms and impacts experienced by patients. The purpose of this study was to explore concepts related to brain fog among SJD patients, and attempt to discern whether brain fog is related to fatigue or may be a separate manifestation as experienced by SJD patients.

Methods: A cross-sectional qualitative study among adults with clinician-confirmed SJD consisted of 30-minute semi-structured concept elicitation (CE) interviews and a pile-sort exercise. A thematic approach, a codebook, and MAXQDA software were used to organize, code, and analyze anonymized CE interview transcripts. In the sorting exercise, patients ranked all items from the Neuro-QoL-Cognitive Function and PROMIS-Cognitive Fatigue item banks as most, somewhat, or not relevant to their brain fog experience. Cultural consensus analysis (CCA) was used to determine whether there were items that participants agreed were most relevant (consensus) that may be considered for a de novo PRO instrument.

Results: Of N=29 SJD patients interviewed (mean age, 63 yrs; 97% female; 79% Caucasian; mean length of time since diagnosis, 13.6 yrs), 75% spontaneously used the term “brain fog” to describe their cognitive difficulties. Symptoms included deficits in memory (96%), concentration (70%), verbalizing (65%), and executive function (59%) (Figure 1, Table 1). Patients reported experiencing brain fog all the time (12%), daily (24%), weekly (36%), monthly (20%) or annually (8%). Results indicated patients generally do not associate brain fog directly with fatigue; of 11 (44%) patients describing brain fog and fatigue as somewhat related, 9 (82%) stated brain fog and fatigue can occur separately while 5 felt fatigue was triggering or causing their brain fog (45%). CCA results from the pile sort exercise indicated that consensus, defined as an Eigenvalue ratio of >3.1, existed among a participant subset (n=10; ER 4.05). Comparing results based on this subset and all patients demonstrated a nearly identical overlap in highly ranked items between the two groups. Neuro-QoL items consistently ranked higher than PROMIS items; 17 of the top 20 highest ranked items were based on the Neuro-QoL, indicating items of cognitive dysfunction were more relevant than those of cognitive fatigue for SJD patients.

Conclusion: Brain fog commonly affects SJD patients with symptoms impacting memory, concentration, verbalization and executive function. Participant endorsement of items from the Neuro-QoL suggests brain fog may be attributable to independent cognitive dysfunction rather than cognitive fatigue. The results support exploring the use of highly ranked Neuro-QoL items to develop a draft de-novo Brain Fog PRO for further research in SJD patients.

Supporting image 1

Supporting image 2


Disclosures: D. Kruzikas: AbbVie/Abbott, 3, 11; A. Eldred: AbbVie/Abbott, 3, 11; S. Kafka: AbbVie/Abbott, 3, 11; J. Church: Sjögren’s Foundation, 3; K. Hammitt: Sjögren’s Foundation, 3; P. Koochaki: ICON Clinical Research LLC, 3, the healthcare business of Merck KGaA, Darmstadt, Germany, 2; C. O'Donnell: ICON plc, 3.

To cite this abstract in AMA style:

Kruzikas D, Eldred A, Kafka S, Church J, Hammitt K, Koochaki P, O'Donnell C. Patient Experience of Brain Fog to Inform the Development of a De Novo Patient Reported Outcome (PRO) in Patients with Sjögren’s Disease [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/patient-experience-of-brain-fog-to-inform-the-development-of-a-de-novo-patient-reported-outcome-pro-in-patients-with-sjogrens-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-experience-of-brain-fog-to-inform-the-development-of-a-de-novo-patient-reported-outcome-pro-in-patients-with-sjogrens-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology